AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15693603
Drug: Mandibular overdenture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular overdenture on two implants (IMP-group)
Trial: 10347961
Drug: Inhalatory corticosteroids
RxNorm normalized name: abiraterone and corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalatory corticosteroids therapy with educational program (EDUCASMA)
Trial: 8562152
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with LV (200 mg/m2) plus 5‐FU (350 mg/m2), both given i.v. (days 1‐4) and i.p. (days 1 and 3) every 4 weeks for a total of six courses
Trial: 8971294
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg hydrocortisone
Trial: 11500348
Drug: Albuterol (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (n = 28)
Trial: 16333385
Drug: Conventional three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional three dose scheme (month 0, 1, 6)
Trial: 16333385
Drug: Two dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two dose brief scheme (month 0, 1)
Trial: 16333385
Drug: Three dose
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three dose brief scheme (month 0, 1, 2)
Trial: 12882862
Drug: Preprandial insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preprandial insulin aspart (immediately before meal start)
Trial: 12882862
Drug: Postprandial insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postprandial insulin aspart (immediately after a meal or a maximum of 30 min after meal start)
Trial: 1377307
Drug: Slow-release verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release verapamil (240 mg once daily)
Trial: 3160356
Drug: Nitrendipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (20 mg once daily)
Trial: 20484610
Drug: Gastric-retentive extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric-retentive extended-release formulation of gabapentin
Trial: 20484610
Drug: Gastric-retentive extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric-retentive extended-release formulation of gabapentin with food
Trial: 20484610
Drug: Immediate-release formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release formulation of gabapentin
Trial: 11012558
Drug: S 17092
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S 17092 800 mg
Trial: 11012558
Drug: S 17092
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S 17092 1200 mg
Trial: 11012558
Drug: S 17092
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S 17092 (all doses)
Trial: 8881815
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg budesonide
Trial: 10950051
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg budesonide
Trial: 1384078
Drug: i.v. opiate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. opiate by un-signalled infusion
Trial: 25659440
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) administration
Trial: 8669327
Drug: Complete hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Complete hormone blockade (CHB)
Trial: 8669327
Drug: Monotherapy (orchidectomy)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (orchidectomy)
Trial: 29857497
Drug: HP diet
RxNorm normalized name: HP 502
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP diet with ≥4 weekly servings of lean beef (B)
Trial: 26417901
Drug: Sublingual liquid
RxNorm normalized name: B Complex with B-12 Sublingual Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual liquid birch pollen preparation (SB) 3333 AUN/ml
Trial: 20500832
Drug: Fluvastatin 80
RxNorm normalized name: fluvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 80 mg
Trial: 9511827
Drug: Antibody response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Antibody response against teichoic acid
Trial: 9511827
Drug: Positive antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive antibody response to at least one of the three antigens
Trial: 30696435
Drug: Combination therapies
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapies
Trial: 24667662
Drug: Three-day regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-day regimen of dihydroartemisinin-piperaquine (total dose 360 mg dihydroartemisinin and 2880 mg piperaquine)
Trial: 20636866
Drug: Topical agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical agents (specific agents not mentioned)
Trial: 16900483
Drug: All-trans-retinoic acid
RxNorm normalized name: all-trans-Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans-retinoic acid (ATRA) at 90 mg/m2/day in three divided doses for 3 consecutive days per week, combined with interferon-α2a (IFN-α2a) at 3 × 106 U/m2/day subcutaneously for 5 consecutive days per week in 4 week cycles.
Trial: 8842905
Drug: Patient controlled
RxNorm normalized name: PATIENT CONTROLLED ANALGESIA VIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient controlled analgesia with morphine (0.015 mg/kg)
Trial: 23433769
Drug: AZD9668 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9668 60 mg twice daily for 4 weeks
Trial: 21334098
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg of daily oral dexamethasone for 2 days
Trial: 21334098
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of daily oral prednisone for 5 days
Trial: 10468681
Drug: Orange juice
RxNorm normalized name: Orange juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange juice (200 mL, 75 mg of 13C-urea)
Trial: 10468681
Drug: Citric acid
RxNorm normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citric acid solution (200 mL, 50 mg of 13C-sodium acetate)
Trial: 25548849
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of botulinum toxin A (BoNT A) after ablative fractional CO2 laser treatment
Trial: 16706244
Drug: Metronidazole 1%
RxNorm normalized name: METRONIDAZOLE 1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 1% gel (once-daily application)
Trial: 18560640
Drug: Sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium fluoride gel
Trial: 17885577
Drug: Clozapine treatment
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine treatment
Trial: 30130627
Drug: Alfuzosin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin (10 mg extended release)
Trial: 30130627
Drug: Alfuzosin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin (2.5 mg immediate release)
Trial: 26004888
Drug: Standard-dose selenium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose selenium supplementation (Se-, n = 75) in SIRS patients
Trial: 21529740
Drug: Atorvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (80 mg 12 hours before intervention with another 40 mg preprocedure dose)
Trial: 6366100
Drug: O-(beta-hydroxyethyl)-rutosides (HR)
RxNorm normalized name: Padimate O
DrugBank: Padimate O (DB11570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: O-(beta-hydroxyethyl)-rutosides (HR) 2 g/day
Trial: 28325013
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy combined with Electrical Stimulation (ES)
Trial: 20211180
Drug: Prolonged low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prolonged low-dose peginterferon-alpha2a therapy and beta-blockers
Trial: 10520842
Drug: Intravenous hyoscyamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hyoscyamine (0.25 mg)
Trial: 25428627
Drug: 5% lidocaine
RxNorm normalized name: LIDOCAINE 5 g in 100 g TOPICAL CREAM [Healcome Tattoo Numbing Cream 5% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% lidocaine patches
Trial: 28701501
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure treatment (systolic BP <140 mm Hg)
Trial: 28430722
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine and bupivacaine injection
Trial: 31887803
Drug: Control (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (normal saline injection)
Trial: 26010427
Drug: Standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doses of peginterferon α-2b plus low and escalating doses of ribavirin (group 1)
Trial: 10715306
Drug: Capecitabine 1,331
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine 1,331 mg/m²/d bid continuously (arm A)
Trial: 9928755
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS 20 mg once daily
Trial: 1304283
Drug: Iopanoic acid
RxNorm normalized name: Iopanoic Acid
DrugBank: Iopanoic acid (DB08946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iopanoic acid (500 mg orally twice a day for the first 3 weeks) and carbimazole (30 mg orally in three divided doses)
Trial: 25500574
Drug: Intramuscular midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular midazolam (0.3 mg/kg)
Trial: 25047312
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam (0.15 mg/kg)
Trial: 12583944
Drug: Intermittent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent chemotherapy (break in chemotherapy, re-starting on the same drug on progression)
Trial: 12583944
Drug: Continuous chemotherapy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous chemotherapy (until progression)
Trial: 10224577
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin by infusion (group II, n = 12)
Trial: 1899455
Drug: Average dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average dialysis treatment duration of less than 3.5 hours
Trial: 1899455
Drug: Average dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average dialysis treatment duration longer than 3.5 hours
Trial: 29415906
Drug: NKCP® (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NKCP® (250 mg daily for 4 weeks)
Trial: 27112031
Drug: Percutaneous radio-frequency
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous radio-frequency ablation with ethanol injection (2.5-9.6 mL) and temperature control at 45-56 °C for more than 10 min.
Trial: 27112031
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (ablation without ethanol injection, lesions more than 5 mm from gastrointestinal tract).
Trial: 7479215
Drug: Non-dialysis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-dialysis treatment
Trial: 19743725
Drug: 3-step acne
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-step acne system (salicylic acid cleanser 2% twice daily, salicylic acid toner 2% once daily, solubilized BPO gel 5% twice daily)
Trial: 19743725
Drug: Control (cleanser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (cleanser twice daily plus clindamycin 1%-BPO 5% gel twice daily)
Trial: 11042828
Drug: hCG injection
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG injection followed by oocyte retrieval at 34 hours (group A)
Trial: 3912695
Drug: Adriamycin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adriamycin (40 mg/m2) and cyclophosphamide (500 mg/m2)
Trial: 3912695
Drug: Adriamycin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adriamycin (40 mg/m2) and cisplatin (50 mg/m2)
Trial: 31117967
Drug: Weekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly cisplatin regimen (30-40 mg/m2 on days 1, 8, 15, 22, 29, 36, and 43)
Trial: 31117967
Drug: Triweekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triweekly cisplatin regimen (80-100 mg/m2 on days 1, 22, and 43)
Trial: 31117967
Drug: Weekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly cisplatin regimen
Trial: 26435363
Drug: Conventional photodynamic
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional photodynamic therapy (c‐PDT)
Trial: 22648722
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (EPA and DHA 600 mg in a 2:1 ratio)
Trial: 16142802
Drug: conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional treatment without GP IIb/IIIa inhibitor (group 2, 70 patients)
Trial: 17207299
Drug: Gabapentin 400
RxNorm normalized name: gabapentin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 400 mg 6 hourly for 7 days plus continuous wound infusion of ropivacaine 0.75% for 30 h
Trial: 17207299
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules identical to those of gabapentin for 7 days and continuous wound infusion of normal saline for 30 h
Trial: 17207299
Drug: Gabapentin and
RxNorm normalized name: Gabapentin and mecobalamin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin and ropivacaine treatment
Trial: 2894911
Drug: propranolol 80
RxNorm normalized name: propranolol 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propranolol 80 mg X 2
Trial: 25592254
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (AQ‐AS, DHA‐PQ, AL, MQAS)
Trial: 21533301
Drug: Glycyrrhetinic acid-containing
RxNorm normalized name: Glycyrrhetinic acid-containing product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycyrrhetinic acid-containing barrier repair cream (BRC-Gly, Atopiclair®)
Trial: 21533301
Drug: Ceramide-dominant barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceramide-dominant barrier repair cream (BRC-Cer, EpiCeram®)
Trial: 10146979
Drug: Clentiazem (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clentiazem (calcium channel blocker)
Trial: 18341664
Drug: Topical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical placebo ointment
Trial: 2934438
Drug: Topical betamethasone
RxNorm normalized name: betamethasone Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betamethasone ointment
Trial: 22030947
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg caffeine (C)
Trial: 22030947
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg caffeine + 50 mg geranamine (C + G 50 mg)
Trial: 22030947
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg caffeine + 75 mg geranamine (C + G 75 mg)
Trial: 18465339
Drug: Nine courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nine courses of three-weekly cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
Trial: 11756615
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g acetaminophen daily (n = 20)
Trial: 3551577
Drug: Copovithane schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copovithane schedule B: 10 g/m2 i.v. over 30 min once a week until progression, unacceptable toxicity, or up to 18 months
Trial: 18515521
Drug: Sinecatechins ointment
RxNorm normalized name: sinecatechins Topical Ointment
DrugBank: Sinecatechins (DB01266)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sinecatechins ointment 10%
Trial: 26719035
Drug: Regular concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular concurrent exercise training for 30 weeks
Trial: 19460078
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of different pacing sites and AF suppression pacing
Trial: 11157369
Drug: High dialysate
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dialysate calcium concentration (HDCa; 3.5 mEq/L)
Trial: 28383533
Drug: One capsule
RxNorm normalized name: GABAdone Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule of daily iron supplement (34 mg of ferrous sulfate)
Trial: 28383533
Drug: Two capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two capsules of daily iron supplement (34 mg of ferrous sulfate)
Trial: 26488676
Drug: Low-dose mirtazapine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose mirtazapine
Trial: 21362764
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 200 mg subcutaneously every 2 weeks for 52 weeks
Trial: 9690695
Drug: ziprasidone 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ziprasidone 160 mg/day
Trial: 9690695
Drug: haloperidol 15
RxNorm normalized name: haloperidol 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: haloperidol 15 mg/day
Trial: 9690695
Drug: ziprasidone 4
RxNorm normalized name: ziprasidone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ziprasidone 4 mg/day
Trial: 9690695
Drug: ziprasidone 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ziprasidone 10 mg/day
Trial: 9690695
Drug: ziprasidone 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ziprasidone 160 mg/day and haloperidol 15 mg/day
Trial: 2568105
Drug: Beta 2
RxNorm normalized name: Beta 2 globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta 2 sympathomimetic drugs administered by aerosol inhaler
Trial: 29514693
Drug: Standard induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard induction therapy (non-MSC treatment)
Trial: 17138156
Drug: Epinephrine infusion
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine infusion at 50 ng/kg per minute under sedation with propofol (4 mg/kg per hour)
Trial: 17138156
Drug: Epinephrine infusion
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epinephrine infusion at 50 ng/kg per minute under sedation with midazolam (0.2 mg/kg per hour)
Trial: 8776195
Drug: Experimental design
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental design approach using a combination of solution concentration, air exchange rate, and body type in a cross-classified design for estimating historical exposures to formaldehyde.
Trial: 25661470
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment only
Trial: 18380741
Drug: Control (antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (antibiotics and analgesics alone)
Trial: 18380741
Drug: Sitz bath
RxNorm normalized name: SITZ BATH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitz bath (twice-daily) along with antibiotics and analgesics
Trial: 20082586
Drug: Nateglinide (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide (120 mg)
Trial: 15477634
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg once daily
Trial: 3629205
Drug: Soft-laser therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft-laser therapy (He-Ne laser, 6 J/cm2, 9 treatments)
Trial: 23893828
Drug: Usual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual therapy alone
Trial: 25632085
Drug: Fingolimod (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod (mean exposure to study drug, 2.4 years)
Trial: 21396848
Drug: Lidocaine-ketorolac gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine-ketorolac gel (5 g 2.5% lidocaine + 0.3% ketorolac tromethamine) 1 hour before TPB
Trial: 16238896
Drug: IV paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV paracetamol 1 g